Curis Lifesciences IPO

Curis Lifesciences Limited is engaged in manufacturing pharmaceutical products such as tablets, capsules, external preparations, oral liquid, sterile ophthalmic ointments. The company’s business model involves the following main activities: loan license manufacturing, contract manufacturing and direct exports. It has served 100+ customers for loan licensing and contract manufacturing, and 2 customers for direct exports/own brand marketing, primarily in Yemen and Kenya. Product wise, major revenue contribution came from tablets, accounting for 87.90% of revenue. Loan license manufacturing contributed 0.98%, contract manufacturing for merchant exports 55.62% and domestic suppliers 43.40% as of July, 2025.